Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis (FIM-BRO-2013)
Primary Purpose
Bronchiectasis
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Pulmonary Rehabilitation
Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate
Sponsored by
About this trial
This is an interventional treatment trial for Bronchiectasis focused on measuring Bronchiectasis.
Eligibility Criteria
Inclusion Criteria:
- Patients ages from 18-80 (both included)
- Patients with bronchiectasis, not cystic fibrosis bronchiectasis.
- Bronchiectasis diagnosed by high resolution computed tomography (HRCT). of the chest
- Patients followed in Bronchiectasis and Cystic Fibrosis Units in the Hospital.
- BMI > 18.5 in patients under 65 years old, and > 20kg/m2 in patients over this age.
- Ambulatory patients.
Exclusion Criteria:
- Use of oral corticoids.
- Respiratory exacerbation. If a patient had a respiratory exacerbation or a recent hospital admission, their participation will be postponed for at least 60 days til any acute disease is resolved.
- Prior oral or parenteral supplements intake.
- Traumatological, neurological or cardiovascular diseases that prevent patients from performing the training.
- Life threatening hemoptysis in the past year.
- Patients with cancer, major surgery in the previous three months, participating in another study, patients who are pregnant or may become pregnant, patients with acute intestinal disease, acute heart failure, severe hepatic failure or dialysis.
- Gastrectomy, gastroparesis or other alterations of gastric emptying.
- Enteral tube feeding, galactosemia, Fructosemia.
- Allergy or known sensitivity to any ingredient of the enteral formula.
- Cystic fibrosis.
- Included in active list for transplantation.
- Drug or alcohol abuse.
- No informed consent signed.
Sites / Locations
- Gabriel Olveira
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Pulmonary Rehabilitation (PRP)
Pulmonary Rehabilitation plus oral nutritional supplement
Arm Description
Pulmonary Rehabilitation (PRP)
Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
Outcomes
Primary Outcome Measures
Change in oxygen uptake at peak exercise (VO2max) in cardiopulmonary exercise test (Before and after Rehabilitation-at 3 and 6 months)
Secondary Outcome Measures
Body composition
Anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance.
Full Information
NCT ID
NCT02048397
First Posted
January 15, 2014
Last Updated
March 15, 2016
Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Collaborators
Fundación Pública Andaluza Progreso y Salud
1. Study Identification
Unique Protocol Identification Number
NCT02048397
Brief Title
Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis
Acronym
FIM-BRO-2013
Official Title
A Pilot Study of Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Collaborators
Fundación Pública Andaluza Progreso y Salud
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The effect of Pulmonary Rehabilitation in patients with bronchiectasis (BC) is not sufficiently studied. The aim of this study is to assess the clinical and biological response of a Pulmonary Rehabilitation Program (PRP) for 12 weeks in BC vs PRP plus hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB).
Methods: single center randomized controlled trial, parallel treatment design: Participants will be randomized assigned either will receive (n=14) PRP for 60 minutes, two supervised sessions per week in the hospital and one unsupervised session at home vs PRP (n=14) plus ONS (one can per day).
Outcome assessments will be performed at baseline, 12 weeks and 24 weeks:
1.- effort capacity –cardiopulmonary exercise test-, 2.- body composition (anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance, phase angle), 3.- peripheral muscle strength (dynamometry and respiratory -PEM (maximum expiratory pressure)and PIM (minimum expiratory pressure)-), 4.- spirometry, 5.- respiratory symptoms (bronchorrhea, dyspnoea, exacerbations),6.- level of physical activity (IPAQ questionnaire plus objective physical activity (WGT3X)), 7.- quality of life (QOL-B-Spain) , 8.-psychological symptoms (HASD) and 9.- biological markers of inflammation (leptin, adiponectin, interleukin-6, tumor necrosis factor-alpha, ultrasensitive C-reactive protein, GPR55 (G protein-coupled receptor 55) RNAm (messenger ribonucleic acid) expression in white blood cells) and oxidation (total antioxidant capacity, superoxide dismutase activity, 8-iso-prostaglandin F2a, Thiobarbituric acid reactive substances).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchiectasis
Keywords
Bronchiectasis.
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pulmonary Rehabilitation (PRP)
Arm Type
Other
Arm Description
Pulmonary Rehabilitation (PRP)
Arm Title
Pulmonary Rehabilitation plus oral nutritional supplement
Arm Type
Other
Arm Description
Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
Intervention Type
Other
Intervention Name(s)
Pulmonary Rehabilitation
Intervention Type
Dietary Supplement
Intervention Name(s)
Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate
Primary Outcome Measure Information:
Title
Change in oxygen uptake at peak exercise (VO2max) in cardiopulmonary exercise test (Before and after Rehabilitation-at 3 and 6 months)
Time Frame
3rd and 6th month visits
Secondary Outcome Measure Information:
Title
Body composition
Description
Anthropometry, lean body mass by dual energy X-ray absorptiometry and bioimpedance.
Time Frame
3rd and 6th month visits
Other Pre-specified Outcome Measures:
Title
Peripheral muscle strength
Description
Dynamometry
Time Frame
3rd and 6th month visits
Title
Change from baseline in respiratory symptoms (bronchorrhea, dyspnea, exacerbations) at 6 months.
Time Frame
3rd and 6th month visits
Title
Level of physical activity
Description
IPAQ questionnaire plus objective physical activity
Time Frame
3rd and 6th month visits
Title
Quality of life
Description
QOL-B-Spain
Time Frame
3rd and 6th month visits
Title
biological markers of Biological markers of inflammation and oxidation
Time Frame
3rd and 6th month visits
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients ages from 18-80 (both included)
Patients with bronchiectasis, not cystic fibrosis bronchiectasis.
Bronchiectasis diagnosed by high resolution computed tomography (HRCT). of the chest
Patients followed in Bronchiectasis and Cystic Fibrosis Units in the Hospital.
BMI > 18.5 in patients under 65 years old, and > 20kg/m2 in patients over this age.
Ambulatory patients.
Exclusion Criteria:
Use of oral corticoids.
Respiratory exacerbation. If a patient had a respiratory exacerbation or a recent hospital admission, their participation will be postponed for at least 60 days til any acute disease is resolved.
Prior oral or parenteral supplements intake.
Traumatological, neurological or cardiovascular diseases that prevent patients from performing the training.
Life threatening hemoptysis in the past year.
Patients with cancer, major surgery in the previous three months, participating in another study, patients who are pregnant or may become pregnant, patients with acute intestinal disease, acute heart failure, severe hepatic failure or dialysis.
Gastrectomy, gastroparesis or other alterations of gastric emptying.
Enteral tube feeding, galactosemia, Fructosemia.
Allergy or known sensitivity to any ingredient of the enteral formula.
Cystic fibrosis.
Included in active list for transplantation.
Drug or alcohol abuse.
No informed consent signed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GABRIEL OLVEIRA, MD, PhD
Organizational Affiliation
Andaluz Health Service
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gabriel Olveira
City
Malaga
ZIP/Postal Code
29009
Country
Spain
12. IPD Sharing Statement
Citations:
Citation
Clin Nutr. 2015 Oct 19. pii: S0261-5614(15)00255-1. doi: 10.1016/j.clnu.2015.10.001. [Epub ahead of print]
Results Reference
background
PubMed Identifier
29952809
Citation
Dona E, Olveira C, Palenque FJ, Porras N, Dorado A, Martin-Valero R, Godoy AM, Espildora F, Olveira G. Pulmonary Rehabilitation Only Versus With Nutritional Supplementation in Patients With Bronchiectasis: A RANDOMIZED CONTROLLED TRIAL. J Cardiopulm Rehabil Prev. 2018 Nov;38(6):411-418. doi: 10.1097/HCR.0000000000000341.
Results Reference
derived
PubMed Identifier
29656933
Citation
Dona E, Olveira C, Palenque FJ, Porras N, Dorado A, Martin-Valero R, Godoy AM, Espildora F, Contreras V, Olveira G. Body Composition Measurement in Bronchiectasis: Comparison between Bioelectrical Impedance Analysis, Skinfold Thickness Measurement, and Dual-Energy X-ray Absorptiometry before and after Pulmonary Rehabilitation. J Acad Nutr Diet. 2018 Aug;118(8):1464-1473. doi: 10.1016/j.jand.2018.01.013. Epub 2018 Apr 12.
Results Reference
derived
PubMed Identifier
26522923
Citation
Olveira G, Olveira C, Dona E, Palenque FJ, Porras N, Dorado A, Godoy AM, Rubio-Martinez E, Rojo-Martinez G, Martin-Valero R. Oral supplement enriched in HMB combined with pulmonary rehabilitation improves body composition and health related quality of life in patients with bronchiectasis (Prospective, Randomised Study). Clin Nutr. 2016 Oct;35(5):1015-22. doi: 10.1016/j.clnu.2015.10.001. Epub 2015 Oct 19.
Results Reference
derived
Learn more about this trial
Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis
We'll reach out to this number within 24 hrs